The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), received a $459,250 Project Grant award from the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The award will fund a 2-year research project to investigate and validate the use of dried blood spot (DBS) samples for measuring Alzheimer's disease (AD) biomarkers, including p-tau217, GFAP, and NfL. The key objectives are to: 1) optimize fingerstick collection methods and validate assays for DBS AD biomarker measurement; 2) establish correlations between DBS and plasma biomarker concentrations; and 3) evaluate the stability of repeated DBS biomarker measurements over 14 weeks. The overarching goal is to assess the feasibility of using frequent, minimally-invasive DBS samples as a sensitive measure of AD pathology for clinical trials and longitudinal research, which could improve diversity and inclusion in such studies.
Generated 3/18/25, 4:00 AM